Theravance Biopharma(Delisted)
- Market cap
- 884.18M
- P/E (TTM)i
- 16.38
- P/Bi
- 3.05
- EPSi
- 2.06
- Div yieldi
- 0.00%
- 52W posi
- 50%
Anonymous reader poll. Unscientific, not investment advice.
About Theravance Biopharma(Delisted)
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
- CEO
- Mr. Rick E. Winningham
- Employees
- 90
- Fiscal year end
- 12-31
- Website
- theravance.com
Company profile
- Exchange
- US
- Symbol
- TBPH
- Market-cap rank
- #3330
- Listing date
- 2015-10-26
- Market cap
- 884.18M
- Float cap
- 440.57M
- Shares out
- 51.92M
- Float shares
- 25.87M
Sectors & themes
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.